Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
May 14, 2024
Read MoreZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
May 12, 2024
Read MoreZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
May 08, 2024
Read MoreZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Apr 15, 2024
Read MoreZai Lab Statement on Executive Management Team’s Agreement on Share Activities
Apr 11, 2024
Read MoreZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
Apr 02, 2024
Read MoreZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Apr 01, 2024
Read More